| scholarly article | Q13442814 |
| P2093 | author name string | M Needham | |
| F L Mastaglia | |||
| P433 | issue | 1 | |
| P304 | page(s) | 4-15 | |
| P577 | publication date | 2013-09-30 | |
| P1433 | published in | Neuromuscular Disorders | Q1981326 |
| P1476 | title | Statin myotoxicity: a review of genetic susceptibility factors | |
| P478 | volume | 24 |
| Q41940315 | Acute rhabdomyolysis associated with coadministration of levofloxacin and simvastatin in a patient with normal renal function |
| Q90060658 | Assessment of concomitant non-oncologic medication in patients with surgically treated renal cell carcinoma: impact on prognosis, cell-cycle progression and proliferation |
| Q36256049 | Association Between SLCO1B1 Gene T521C Polymorphism and Statin-Related Myopathy Risk: A Meta-Analysis of Case-Control Studies |
| Q37014008 | Bringing Bioactive Compounds into Membranes: The UbiA Superfamily of Intramembrane Aromatic Prenyltransferases |
| Q90482667 | Clinical features related to statin-associated muscle symptoms |
| Q94457796 | Effect of Camellia sinensis teas on left ventricular hypertrophy and insulin resistance in dyslipidemic mice |
| Q58123832 | Effects of Coenzyme Q10 on Statin-Induced Myopathy: An Updated Meta-Analysis of Randomized Controlled Trials |
| Q33988933 | Effects of poly-bioactive compounds on lipid profile and body weight in a moderately hypercholesterolemic population with low cardiovascular disease risk: a multicenter randomized trial |
| Q38415231 | Emerging PCSK9 inhibitors for treating dyslipidaemia: buttressing the gaps in coronary prevention. |
| Q50054110 | Genetic variation in statin intolerance and a possible protective role for UGT1A1. |
| Q55353903 | LDL-cholesterol lowering effect of a new dietary supplement: an open label, controlled, randomized, cross-over clinical trial in patients with mild-to-moderate hypercholesterolemia. |
| Q38924930 | Laboratory Medicine in the Clinical Decision Support for Treatment of Hypercholesterolemia: Pharmacogenetics of Statins |
| Q35501523 | Lack of pharmacokinetic interactions between pitavastatin and efavirenz or darunavir/ritonavir |
| Q34221540 | Lipin-1 regulates autophagy clearance and intersects with statin drug effects in skeletal muscle |
| Q37218787 | Mood, Personality, and Behavior Changes During Treatment with Statins: A Case Series |
| Q39318070 | Muscular hypertonicity: a suspected contributor to rheumatological manifestations observed in ambulatory practice |
| Q28275648 | PCSK9 Inhibition With Monoclonal Antibodies: Modern Management of Hypercholesterolemia |
| Q38644316 | Patients experiencing statin-induced myalgia exhibit a unique program of skeletal muscle gene expression following statin re-challenge |
| Q34163351 | Pharmacogenetics of Statin-Induced Myopathy: A Focused Review of the Clinical Translation of Pharmacokinetic Genetic Variants |
| Q38203774 | Pharmacogenomics, lipid disorders, and treatment options |
| Q41526681 | Review of the Reported Measures of Clinical Validity and Clinical Utility as Arguments for the Implementation of Pharmacogenetic Testing: A Case Study of Statin-Induced Muscle Toxicity |
| Q34047690 | Rhabdomyolysis after midazolam administration in a cirrhotic patient treated with atorvastatin |
| Q35669829 | SLCO1B1 polymorphism is not associated with risk of statin-induced myalgia/myopathy in a Czech population |
| Q35232279 | Statin intolerance - an attempt at a unified definition. Position paper from an International Lipid Expert Panel |
| Q38430744 | Statin intolerance: diagnosis and remedies |
| Q38228757 | Statin myopathy: the fly in the ointment for the prevention of cardiovascular disease in the 21st century? |
| Q28083004 | Statin-associated muscle symptoms: impact on statin therapy-European Atherosclerosis Society Consensus Panel Statement on Assessment, Aetiology and Management |
| Q44739535 | Statin-induced muscle toxicity and susceptibility to malignant hyperthermia and other muscle diseases: a population-based case-control study including 1st and 2nd degree relatives |
| Q41516471 | The adjuvant value of Herba Cistanches when used in combination with statin in murine models. |
| Q38492567 | The role of mitochondria in statin-induced myopathy |
| Q27007256 | Toxic myopathies |
| Q36294394 | Treatment Options for Statin-Associated Muscle Symptoms |
| Q88218979 | [Risk genes in myopathies and mitochondrial diseases] |
| Q53649484 | [Statin intolerance and associated muscular dysfunctions]. |
Search more.